Adverse drug reaction profile of oseltamivir in children

Journal of Pharmacology and Pharmacotherapeutics

Volumn 2, Issue 2, 2011, Pages 100-103

  Dalvi, Prashant S ^a   Singh, Anil ^a   Trivedi, Hiren R ^a   Mistry, Suresh D ^a   Vyas, Bhadresh R ^a  

^a MP Shah Medical College   (India)

Author keywords

Adverse drug reactions; antiviral agent; child; infant; oseltamivir

Indexed keywords

OSELTAMIVIR;

ABDOMINAL PAIN; ADVERSE OUTCOME; AGE DISTRIBUTION; ARTICLE; CAUSAL ATTRIBUTION; CHEMOPROPHYLAXIS; CHILD; CHILD HEALTH CARE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG ERUPTION; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; EAR DISEASE; EPISTAXIS; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFANT; INFECTION PREVENTION; INFLUENZA A (H1N1); INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; NAUSEA; PNEUMONIA; PRESCHOOL CHILD; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SINUSITIS; TERTIARY HEALTH CARE; VERTIGO; VOMITING;

EID: 84859535608     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.81901     Document Type: Article

References (20)

1. Le J, Nguyen T, Law AV, Hodding J. Adverse Drug Reactions Among Children Over a 10-Year Period. Pediatrics 2006;118:555-62.
2. Health Canada. Reporting Adverse Reactions to Antiviral Drugs During an Influenza Pandemic-Guidelines for Health Professionals and Consumers. [Updated 2009 May 8]. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb- dgpsa/pdf/medeff/2009-ar-ei-anti-guide-ldir-eng.pdf. [Cited on 2010 May 8].
3. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: A systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001;52:77-83.
4. Dharnidharka VR, Kandoth PN, Anaud RK. Adverse drug reaction in paediatrics with a study of in-hospital intensive surveillance. Indian paediatr 1993;30:745-51.
5. Kshirsagar NA, Karande S. Adverse Drug Reaction Monitoring in Pediatric Practice. Indian Paediatr 1996;33:993-8.
6. McNicholl IR, McNicholl JJ. Neuraminidase inhibitors: Zanamivir and oseltamivir. Ann Pharmacother 2001;35:57-70.
7. Tamiflu product information. Roche Pharmaceuticals. [Updated 2000 Dec]. Available from: http://www.rocheusa.com/products/tamiflu/pi-only.htm [Cited on 2010 May 7].
8. Department of Health and Human Services, Public Health Service, Food and Drug Administration Center for Drug Evaluation and Research. Memorandum ODS PID#: D060309. [Updated 2006 Sep 20]. Available at: http://www.fda.gov/ohrms/ dockets/ac/06/briefing/2006-4254b-09-01-Tamiflu%20AE%20Review%202006%20Redacted- D060309-092.pdf. [Cited on 2010 May 5].
9. Maxwell SR. Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 2007;334:1232-3.
10. US Food and Drug Administration. Alert letter. [2003 Dec]. Available from: http://www.fda.gov/medwatch/SAFETY/2003/tamiflu-deardoc.pdf. [Cited on 2010 May 8].
11. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2007;1:CD002744.
12. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner DA, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: Systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235-9.
13. Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Guidelines on categorization of Influenza A H1N1 cases during screening for home isolation, testing treatment, and hospitalization. Available from: http://www.mohfw-h1n1.nic.in/documents/pdf/3. categorizationofinfluenzaAH1N1casesscreening.pdf. [Cited on 2010 May 8].
14. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three london schools affected by influenza A(H1N1)v, May 2009 - an internet based cross sectional survey. Euro Surveill 2009;14:1-4.
15. Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: Case series and overview of causal relationships. Int J Risk Safety Med 2008;20:5-36.
16. US Food and Drug Administration (FDA). Tamiflu Pediatric Adverse Events: Questions and Answers. [Updated 2005 Nov 17]. Available from: http://www.fda.gov/Cder/Drug/infopage/tamiflu/QA20051117.htm. [Cited on 2010 May 7].
17. Nicholson KG. Clinical features of influenza. Semin Respir Infect 1992;7:26-37.
18. Emergency dosing recommendations for treatment and prophylaxis of influenza in pediatric patients less than 1 year old. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM153546. pdf [Cited on 2010 May 10].
19. Tamura D, Miura T, Kikuchi Y. Oseltamivir Phosphate in Infants Under 1 Year of Age with Influenza Infection. Pediatr Int 2005;47:484.
20. Okamato S, Kamiya I, Kishida K, Fukui T, Morimoto T. Experience with Oseltamivir for Infants Younger than 1 year old in Japan. Pediatr Infect Dis J 2005;24:575-6.